In connection with the transaction, Centogene GmbH will receive funding to provide it with liquidity to the closing date. Centogene N.V. shall further be relieved of all existing liabilities owing to its senior secured lender Oxford Finance LLC. The sale transaction is expected to close in the first quarter of 2025. Following the closing of the transaction, Centogene N.V. and its remaining subsidiaries will no longer have any operations and is expected to enter dissolution and liquidation.
The team further consisted of Nina Kielman, Joppe Schoute, Marloes van der Laan, Eline Keuning, and Stefan Wissing.
About Centogene
Centogene is dedicated to advancing precision medicine for rare and neurodegenerative diseases by combining multiomic technologies with its extensive Biodatabank. This data-driven approach enhances diagnostic speed and accuracy, informs physicians on disease states, and accelerates pharma’s drug discovery and development. Since 2006, CENTOGENE has collaborated with approximately 30,000 physicians and maintains certified labs in Germany, with a database of over 850,000 patients from 120+ countries, contributing to 300+ peer-reviewed studies. Their partnerships with pharmaceutical companies aim to de-risk and expedite drug development, offering valuable data insights to help combat rare diseases.